Agilent Technologies Inc. (NYSE: A) has received two 2022 Scientists’ Choice Awards for Drug Discovery & Development; Virtual Event of the Year, and Innovative Content of the Year. Announced at the SLAS2022 International Conference & Exhibition on February 7th, 2022, the Scientists’ Choice Awards recognize the world’s most innovative and effective analytical science technologies and communications.

The Drug Discovery & Development Virtual Event of the Year was awarded to Agilent for its Pioneers in Biopharma event, in which the scientific community were invited to meet the leaders steering the industry in a one-day event to celebrate and support women in biopharma.

“We are delighted to receive an award for this event that showcased three female pioneers in biopharma,” said Jennifer Gushue associate vice president of Mass Spectrometry Marketing at Agilent. “It is a well-known fact that women are under-represented in science and technology, and our intention was to inspire through highlighting the impact that these scientists have on the ever-evolving field of biopharma.”

The Drug Discovery & Development Innovative Content of the Year award was presented to Agilent for its Robust Analytical Characterization: Accurate, Reliable Quantitation for Biotherapeutics digital campaign. An interactive guide on the chromatographic applications for critical quality attribute monitoring within the most common bioanalysis workflows.

“We are excited to offer researchers valuable information on their journey to develop and analyze next-generation biotherapeutic molecules,” said Daniel Braunschweig, marketing director for Biopharma Columns & Consumables at Agilent. “We hope this consolidated, easy to navigate content-rich site aids researchers in their efforts to obtain reliable, robust analytical results.”

MOBIE, a high-resolution ion mobility (HRIM) system from MOBILion that can be coupled to Agilent’s Q-TOF mass spectrometers, won Drug Discovery & Development Product of 2021 award from Select Science, while Agilent’s Oligo Pro II System, a UV-based parallel capillary electrophoresis platform for the rapid analysis of oligonucleotides, was included as a runner-up.